Inpatient Management of Mucocutaneous GVHD | Zendy

Toral Vaidya | Zendy; Christian Menzer | Zendy; Doris M. Ponce | Zendy; Alina Markova | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inpatient Management of Mucocutaneous GVHD

Author(s) -

Toral Vaidya,

Christian Menzer,

Doris M. Ponce,

Alina Markova

Publication year - 2019

Publication title -

current dermatology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.314

H-Index - 13

ISSN - 2162-4933

DOI - 10.1007/s13671-019-00280-3

Subject(s) - medicine , mucocutaneous zone , graft versus host disease , disease , hematopoietic stem cell transplantation , basiliximab , immunosuppression , ibrutinib , transplantation , immunology , intensive care medicine , dermatology , leukemia , tacrolimus , chronic lymphocytic leukemia

Graft-versus-host disease (GVHD) is an immune mediated disorder affecting 30 - 70% of patients after allogeneic hematopoietic stem cell transplantation (alloHSCT), and is a major cause of morbidity and non-relapse mortality (NRM) [1]. Dermatologists play a critical role in acute and chronic GVHD, as skin involvement is common and often the earliest involved site of disease [2].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research